Actively Recruiting
The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
Led by Shengjing Hospital · Updated on 2022-09-13
200
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To observe the efficiency for patient with stage II-III HR+/HER2+ early breast cancer with standard neoadjuvant therapy, a retrospective, multicenter study in real world settings.
CONDITIONS
Official Title
The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosis of HR+/HER2+ breast cancer based on local standards
- Women diagnosed with stage II-III breast cancer according to AJCC 8th edition
- Planned to receive standard therapy (TCbHP, THP, EC-THP, or AC-THP) as determined by investigator
- Complete medical history available
- Karnofsky Performance Status score of 70 or above
You will not qualify if you...
- Prior anti-tumor treatment including chemotherapy, radiotherapy, molecular targeted therapy, or endocrine therapy
- Pregnant or breastfeeding women
- Diagnosis of bilateral breast cancer, inflammatory breast cancer, or occult breast cancer
- Stage IV breast cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110004
Actively Recruiting
Research Team
N
Nan Niu, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here